Hongene Biotech

Hongene Biotech Corporation is a global nucleic acid CDMO (contract development and manufacturing organization) and raw materials supplier specializing in oligonucleotide and mRNA therapeutics. Founded in 1998 as one of the first companies dedicated to nucleic acid raw materials, Hongene has grown over nearly three decades into a full-service CDMO partner, providing phosphoramidites, cap analogs, GalNAc conjugates, LNP devices, and custom synthesis for both oligonucleotide and mRNA drug programs. The company's proprietary technology platforms include chemoenzymatic ligation for high-purity siRNA and sgRNA production, and HiXCap cap analogs designed to enhance mRNA translation efficiency. With ISO- and GMP-compliant manufacturing facilities in Shanghai, Union City (California), Hamburg, and Tokyo, Hongene supports biopharma clients from early discovery through commercial manufacturing across RNA therapeutics, gene editing, and mRNA vaccine programs.